{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:47:15Z","timestamp":1769316435631,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001789","name":"Bond University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001789","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bond University Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>The \u03b2<jats:sub>3<\/jats:sub>-agonist mirabegron is thought to induce relaxation of the detrusor muscle, contributing to the improvement of overactive bladder symptoms. There has been recent interest in purposing mirabegron as a medical expulsive therapy drug to improve the passage of smaller kidney stones by relaxing the ureteral smooth muscles. The aim of this study was to determine the effects of mirabegron on the activity of the ureter. Additionally, we investigated the receptor and mechanisms through which mirabegron exerts these effects. In vitro agonist-induced responses of isolated porcine distal ureteral tissues were measured in the absence and presence of mirabegron in organ bath experiments. The responses were expressed as frequency, area under the curve and maximum amplitude. Mirabegron at concentrations of 100\u00a0nM and lower failed to suppress phenylephrine- or 5-HT-induced contractions in the porcine ureteral strip. Mirabegron at 1\u00a0\u03bcM and 10\u00a0\u03bcM produced a rightward shift of phenylephrine concentration\u2013response curves in these tissues. This effect of mirabegron (10\u00a0\u03bcM) was not present in 5-HT concentration\u2013response curves. The mirabegron effect on phenylephrine-induced contractions was also not abolished by \u03b2-adrenoceptor antagonist SR 59230A (10\u00a0\u03bcM), \u03b2-adrenoceptor antagonist propranolol (10\u00a0\u03bcM), \u03b1<jats:sub>2<\/jats:sub>-adrenoceptor antagonist yohimbine (30\u00a0nM), and nitric oxide synthase inhibitor <jats:sc>l<\/jats:sc>-NNA (10\u00a0\u03bcM). The present results show that mirabegron suppresses ureteral contractile responses in the porcine ureter via \u03b1<jats:sub>1<\/jats:sub>-adrenoceptor antagonism, since their effects were not present when the tissues were contracted with 5-HT. Furthermore, the inhibitory effects by mirabegron were not affected by \u03b2<jats:sub>3<\/jats:sub>-adrenoceptor antagonists.<\/jats:p>","DOI":"10.1007\/s00210-022-02244-0","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T14:03:12Z","timestamp":1650549792000},"page":"839-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mirabegron attenuates porcine ureteral contractility via \u03b11-adrenoceptor antagonism"],"prefix":"10.1007","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5866-8968","authenticated-orcid":false,"given":"Iris","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7991-4117","authenticated-orcid":false,"given":"Russ","family":"Chess-Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"2244_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","volume":"173","author":"EC Alexandre","year":"2016","unstructured":"Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, da Silva KP, Ferreira R et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol 173:415\u2013428","journal-title":"Br J Pharmacol"},{"key":"2244_CR2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.juro.2016.05.090","volume":"196","author":"D Assimos","year":"2016","unstructured":"Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP et al (2016) Surgical Management of Stones: American Urological Association\/Endourological Society Guideline, PART I. J Urol 196:1153\u20131160","journal-title":"J Urol"},{"key":"2244_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bju.14454","volume":"122","author":"T Campschroer","year":"2018","unstructured":"Campschroer T, Zhu XY, Vernooij RWM, Lock TMTW (2018) alpha-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. Bju Int 122:932\u2013945","journal-title":"Bju Int"},{"key":"2244_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00240-013-0605-4","volume":"42","author":"E El-Barky","year":"2014","unstructured":"El-Barky E, Ali Y, Sahsah M, Terra AA, Kehinde EO (2014) Site of impaction of ureteric calculi requiring surgical intervention. Urolithiasis 42:67\u201373","journal-title":"Urolithiasis"},{"key":"2244_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/1440-1681.12779","volume":"44","author":"OS Folasire","year":"2017","unstructured":"Folasire OS, Chess-Williams R, Sellers DJ (2017) Inhibitory effect of the urothelium\/lamina propria on female porcine urethral contractility & effect of age. Clin Exp Pharmacol Physiol 44:954\u2013960","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2244_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1600-0773.1978.tb02244.x","volume":"43","author":"A Forman","year":"1978","unstructured":"Forman A, Andersson KE, Henriksson L, Rud T, Ulmsten U (1978) Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol Toxicol (copenh) 43:111\u2013118","journal-title":"Acta Pharmacol Toxicol (copenh)"},{"key":"2244_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11934-021-01066-6","volume":"22","author":"K Gillams","year":"2021","unstructured":"Gillams K, Juliebo-Jones P, Juliebo SO, Somani BK (2021) Gender differences in kidney stone disease (KSD): findings from a systematic review. Curr Urol Rep 22:50","journal-title":"Curr Urol Rep"},{"key":"2244_CR8","doi-asserted-by":"publisher","first-page":"666047","DOI":"10.3389\/fphar.2021.666047","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R, Liu Y, Ciotkowska A, Tamalunas A, Waidelich R, Strittmatter F et al (2021) Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate. Front Pharmacol 12:666047","journal-title":"Front Pharmacol"},{"key":"2244_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","volume":"386","author":"Y Igawa","year":"2013","unstructured":"Igawa Y, Michel MC (2013) Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 386:177\u2013183","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2244_CR10","first-page":"935","volume":"10","author":"M Imran","year":"2013","unstructured":"Imran M, Najmi AK, Tabrez S (2013) Mirabegron for overactive bladder: a novel, first-in-class beta3-agonist therapy. Urol J 10:935\u2013940","journal-title":"Urol J"},{"key":"2244_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1442-2042.2007.01812.x","volume":"14","author":"Y Itoh","year":"2007","unstructured":"Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K (2007) Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 14:749\u2013753","journal-title":"Int J Urol"},{"key":"2244_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00210-015-1097-2","volume":"388","author":"SH Kang","year":"2015","unstructured":"Kang SH, McDermott C, Farr S, Chess-Williams R (2015) Enhanced urothelial ATP release and contraction following intravesical treatment with the cytotoxic drug, doxorubicin. Naunyn Schmiedebergs Arch Pharmacol 388:773\u2013780","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2244_CR13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G et al (2012) Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34:2144\u20132160","journal-title":"Clin Ther"},{"key":"2244_CR14","doi-asserted-by":"publisher","first-page":"106661","DOI":"10.1016\/j.vascn.2019.106661","volume":"102","author":"I Lim","year":"2020","unstructured":"Lim I, Chess-Williams R, Sellers D (2020) A porcine model of ureteral contractile activity Influences of age, tissue orientation, region, urothelium, COX and NO. J Pharmacol Toxicol Methods 102:106661","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2244_CR15","doi-asserted-by":"publisher","first-page":"O209","DOI":"10.1111\/luts.12247","volume":"11","author":"T Maki","year":"2019","unstructured":"Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M et al (2019) Mirabegron induces relaxant effects via cAMP signaling-dependent and -independent pathways in detrusor smooth muscle. Low Urin Tract Symptoms 11:O209\u2013O217","journal-title":"Low Urin Tract Symptoms"},{"key":"2244_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1442-2042.2012.03199.x","volume":"20","author":"R Matsumoto","year":"2013","unstructured":"Matsumoto R, Otsuka A, Suzuki T, Shinbo H, Mizuno T, Kurita Y et al (2013) Expression and functional role of beta3 -adrenoceptors in the human ureter. Int J Urol 20:1007\u20131014","journal-title":"Int J Urol"},{"key":"2244_CR17","doi-asserted-by":"publisher","first-page":"173632","DOI":"10.1016\/j.ejphar.2020.173632","volume":"889","author":"MC Michel","year":"2020","unstructured":"Michel MC (2020) alpha1-adrenoceptor activity of beta-adrenoceptor ligands - An expected drug property with limited clinical relevance. Eur J Pharmacol 889:173632","journal-title":"Eur J Pharmacol"},{"key":"2244_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1124\/jpet.119.264143","volume":"372","author":"MC Michel","year":"2020","unstructured":"Michel MC, Murphy TJ, Motulsky HJ (2020) New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. J Pharmacol Exp Ther 372:136\u2013147","journal-title":"J Pharmacol Exp Ther"},{"key":"2244_CR19","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/bph.13897","volume":"174","author":"W Mo","year":"2017","unstructured":"Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P (2017) The beta3 -adrenoceptor agonist mirabegron increases human atrial force through beta1 -adrenoceptors: an indirect mechanism? Br J Pharmacol 174:2706\u20132715","journal-title":"Br J Pharmacol"},{"key":"2244_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejphar.2012.12.022","volume":"700","author":"T Sakai","year":"2013","unstructured":"Sakai T, Kasahara K, Tomita K, Ikegaki I, Kuriyama H (2013) Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats. Eur J Pharmacol 700:194\u2013200","journal-title":"Eur J Pharmacol"},{"issue":"762","key":"2244_CR21","first-page":"e713","volume":"77","author":"S Sasaki","year":"2011","unstructured":"Sasaki S, Tomiyama Y, Kobayashi S, Kojima Y, Kubota Y, Kohri K (2011) Characterization of alpha1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology 77(762):e713-767","journal-title":"Urology"},{"key":"2244_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s11255-017-1667-y","volume":"49","author":"H Shen","year":"2017","unstructured":"Shen H, Chen Z, Mokhtar AD, Bi X, Wu G, Gong S et al (2017) Expression of beta-adrenergic receptor subtypes in human normal and dilated ureter. Int Urol Nephrol 49:1771\u20131778","journal-title":"Int Urol Nephrol"},{"key":"2244_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","volume":"699","author":"J Svalo","year":"2013","unstructured":"Svalo J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P (2013) The novel beta3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol 699:101\u2013105","journal-title":"Eur J Pharmacol"},{"key":"2244_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/iju.14700","volume":"29","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Mishima Y, Kuroishi K, Ukai M (2022) Efficacy of mirabegron, a beta3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol 29:7\u201315","journal-title":"Int J Urol"},{"key":"2244_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2019-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642\u2013647","journal-title":"J Pharmacol Exp Ther"},{"key":"2244_CR26","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1007\/s00345-021-03772-9","volume":"39","author":"QL Tang","year":"2021","unstructured":"Tang QL, Wang DJ, Zhou S, Tao RZ (2021) Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study. World J Urol 39:4465\u20134470","journal-title":"World J Urol"},{"key":"2244_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejps.2012.03.001","volume":"46","author":"S Tasler","year":"2012","unstructured":"Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, Ney P (2012) An aryloxypropanolamine h\u03b23-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci 46:381\u2013387","journal-title":"Eur J Pharm Sci"},{"key":"2244_CR28","unstructured":"U.S. Food and Drug Administration (2012) Full prescribing information for MYRBETRIQ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202611s011lbl.pdf"},{"key":"2244_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1124\/jpet.120.000301","volume":"377","author":"S Yamada","year":"2021","unstructured":"Yamada S, Chimoto J, Shiho M, Okura T, Morikawa K, Wakuda H et al (2021) Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder. J Pharmacol Exp Ther 377:201\u2013206","journal-title":"J Pharmacol Exp Ther"},{"key":"2244_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/nau.22919","volume":"36","author":"M Zaitouna","year":"2017","unstructured":"Zaitouna M, Alsaid B, Lebacle C, Timoh KN, Benoit G, Bessede T (2017) Origin and nature of pelvic ureter innervation. Neurourol Urodyn 36:271\u2013279","journal-title":"Neurourol Urodyn"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-022-02244-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:21:13Z","timestamp":1655094073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-022-02244-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2244"],"URL":"https:\/\/doi.org\/10.1007\/s00210-022-02244-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal tissues utilised in this study were obtained from an abattoir after slaughter for food and were considered waste and therefore, did not require ethical approval by the institutional committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}